296 results on '"CALVO, VIRGINIA"'
Search Results
2. Sexual dysfunction in patients with cancer, a challenge in oncology practice: results of the CLARIFY project
3. Difficulties on the access to innovative targeted therapies for lung cancer in Spain
4. Machine Learning-Assisted Recurrence Prediction for Early-Stage Non-Small-Cell Lung Cancer Patients
5. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
6. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)
7. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
8. Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7
9. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk
10. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
11. Transvaginal radiofrequency ablation: a therapeutic option for managing symptomatic uterine fibroids in women with reproductive desires
12. Immunogenicity of COVID-19 vaccines in lung cancer patients
13. Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits
14. IASIS and BigMedilytics: Towards personalized medicine in Europe
15. A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL)
16. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
17. Children with Autism and Picture Books: Extending the Reading Experiences of Autistic Learners of Primary Age
18. Perinatal outcomes of pregnancies resulting from assisted reproduction technology in SARS-CoV-2-infected women: a prospective observational study
19. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
20. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
21. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation
22. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer
23. Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
24. Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
25. Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits
26. Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department
27. Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
28. Machine Learning Survival Models for Relapse Prediction in a Early Stage Lung Cancer Patient
29. Association of quality of life with performance status, circadian rhythm, and activity level of lung cancer patients using wearable devices as ambulatory monitoring
30. DetectingALK,ROS1andRETfusions and theMETΔex14splicing variant in liquid biopsies of non‐small cell lung cancer patients using RNA ‐based techniques
31. Data from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
32. Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
33. Supplementary Data 1 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
34. Long‐term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population
35. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden
36. Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA‐based techniques.
37. Cost-effectiveness of diagnostic tests during follow-up in lung cancer patients: an evidence-based study
38. Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
39. Machine Learning–Assisted Recurrence Prediction for Patients With Early-Stage Non–Small-Cell Lung Cancer.
40. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
41. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
42. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
43. An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study
44. Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy
45. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
46. Prospective evaluation of the prognostic value of circulating tumor DNA in patients with follicular lymphoma: A pilot study.
47. Risk factors for cardiovascular events in patients treated with immunotherapy.
48. Measuring the great objective: Have we transferred the increase in overall survival in stage IV non-small cell lung cancer from clinical trials to clinical practice?
49. Prognostic value of event‐free survival at 12 and 24 months and long‐term mortality for non‐Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group
50. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.